Donal Brennan

@donalb5

UCD Professor of Gynaecological Oncology, Consultant Gynaecological Oncologist, Mater Hospital Dublin.
Opinions are my own

Dublin City, Ireland ucd.ie/medicine/study… Joined July 2011

646 Following 2.7K Followers 1.9K Posts

Latest posts 5

Donal Brennan @donalb5 Nov 21, 2025

Delighted to see the NCTOG Final Report published yesterday. Looking forward to the next phase as Ireland develops an internationally competitive , robust, cost efficient and equitable clinical trial infrastructure.

gov.ie/en/department-…

www.gov.ie Minister for Health publishes recommendations aimed at transforming Ireland’s Clinical Trials... The recommendations follow 12 months of detailed deliberations by the National Clinical Trials Oversight Group (NCTOG)

Donal Brennan @donalb5 Jun 27, 2025

Great to see these in print - trying to support clinical trial activity in Ireland. Thanks to all involved

Department of Health @roinnslainte Jun 26, 2025

Guidance on Data Protection Impact Assessment responsibilities when setting up and conducting a clinical trial has now been published by the National Clinical Trials Oversight Group.

View quoted post on X

Donal Brennan @donalb5 Jun 17, 2025

Delighted to share our paper led by an amazing post doc @donagh_egan and Dr Kate Glennon who developed a framework to temporally order HGSOC tumour samples based on their proteomic expression profiles providing novel insights into metastatic progression.

nature.com/articles/s4169…

Donal Brennan @donalb5 Jun 12, 2025

ASCO® 2025 Insights: Impact of Elinzanetant on Sleep and QoL in Women Receiving Adjuvant Endocrine Therapy for Breast Cancer - The OASIS-4 Trial | VuMedi vumedi.com/video/ascor-20… via @vumedi

www.vumedi.com ASCO® 2025 Insights: Impact of Elinzanetant on Sleep and QoL in Women Receiving Adjuvant Endocrine... A video from Donal Brennan (as part of 2025 ASCO® Annual Meeting Insights Hub), posted on Jun 5, 2025.

Donal Brennan @donalb5 Jun 2, 2025

So proud to see this published- special thanks to all of the brave women who participated in this practice changing study @UCDMedicine @cancertrials_ie @PrecisionOncIre @UCD_Research @ESGO_society @IGCSociety @Isgoppi

NEJM Verified account @NEJM Jun 2, 2025

Presented at #ASCO25:

In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results: nej.md/3FnKwU7

Editorial: Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option nej.md/4jg4sqb

@ASCO
View quoted post on X